The WCLC 2026 conference highlighted emerging data that could establish a new treatment standard for aggressive lung tumors. Additionally, discussions arose regarding the reliability of results from studies conducted in China, raising questions about data integrity in global research.

Cullinan Therapeutics and Taiho Oncology plan to file for FDA approval of zipalertinib for first-line treatment of lung cancer, despite three patient deaths during trials. Analysts suggest the drug's survival benefits may outweigh safety concerns, with a second-line review decision expected early next year.

BioNTech, Summit Therapeutics, GSK, and Roche presented promising findings at the World Conference on Lung Cancer, showcasing overall survival benefits in various lung cancer types. These advancements highlight the potential of next-generation therapies in improving patient outcomes.

New data reveals that the Amivantamab regimen achieves a nearly three-year median overall survival for patients with EGFR Ex20ins lung cancer. This significant finding underscores the potential of Amivantamab in treating this challenging subset of lung cancer.

New data from a trial shows that Akeso's ivonescimab, a bispecific antibody, provides a survival benefit for lung cancer patients compared to Merck's Keytruda. This promising result could impact treatment protocols for lung cancer.